183 related articles for article (PubMed ID: 16061668)
1. Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan.
Tyminski E; Leroy S; Terada K; Finkelstein DM; Hyatt JL; Danks MK; Potter PM; Saeki Y; Chiocca EA
Cancer Res; 2005 Aug; 65(15):6850-7. PubMed ID: 16061668
[TBL] [Abstract][Full Text] [Related]
2. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene.
Pawlik TM; Nakamura H; Mullen JT; Kasuya H; Yoon SS; Chandrasekhar S; Chiocca EA; Tanabe KK
Cancer; 2002 Sep; 95(5):1171-81. PubMed ID: 12209705
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
4. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
Metz MZ; Gutova M; Lacey SF; Abramyants Y; Vo T; Gilchrist M; Tirughana R; Ghoda LY; Barish ME; Brown CE; Najbauer J; Potter PM; Portnow J; Synold TW; Aboody KS
Stem Cells Transl Med; 2013 Dec; 2(12):983-92. PubMed ID: 24167321
[TBL] [Abstract][Full Text] [Related]
5. Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector.
Ichikawa T; Petros WP; Ludeman SM; Fangmeier J; Hochberg FH; Colvin OM; Chiocca EA
Cancer Res; 2001 Feb; 61(3):864-8. PubMed ID: 11221871
[TBL] [Abstract][Full Text] [Related]
6. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy.
Chase M; Chung RY; Chiocca EA
Nat Biotechnol; 1998 May; 16(5):444-8. PubMed ID: 9592392
[TBL] [Abstract][Full Text] [Related]
7. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma.
Danks MK; Yoon KJ; Bush RA; Remack JS; Wierdl M; Tsurkan L; Kim SU; Garcia E; Metz MZ; Najbauer J; Potter PM; Aboody KS
Cancer Res; 2007 Jan; 67(1):22-5. PubMed ID: 17210679
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
Kambara H; Saeki Y; Chiocca EA
Cancer Res; 2005 Dec; 65(24):11255-8. PubMed ID: 16357128
[TBL] [Abstract][Full Text] [Related]
9. A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38.
Stubdal H; Perin N; Lemmon M; Holman P; Bauzon M; Potter PM; Danks MK; Fattaey A; Dubensky T; Johnson L
Cancer Res; 2003 Oct; 63(20):6900-8. PubMed ID: 14583489
[TBL] [Abstract][Full Text] [Related]
10. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies.
Aghi M; Chou TC; Suling K; Breakefield XO; Chiocca EA
Cancer Res; 1999 Aug; 59(16):3861-5. PubMed ID: 10463570
[TBL] [Abstract][Full Text] [Related]
11. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity.
Friedman A; Tian JP; Fulci G; Chiocca EA; Wang J
Cancer Res; 2006 Feb; 66(4):2314-9. PubMed ID: 16489036
[TBL] [Abstract][Full Text] [Related]
12. Enzyme-prodrug systems: carboxylesterase/CPT-11.
Danks MK; Potter PM
Methods Mol Med; 2004; 90():247-62. PubMed ID: 14657567
[No Abstract] [Full Text] [Related]
13. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
14. Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs.
Kasai K; Nakashima H; Liu F; Kerr S; Wang J; Phelps M; Potter PM; Goins WB; Fernandez SA; Chiocca EA
Mol Ther Nucleic Acids; 2013 Aug; 2(8):e113. PubMed ID: 23922029
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.
Otsuki A; Patel A; Kasai K; Suzuki M; Kurozumi K; Chiocca EA; Saeki Y
Mol Ther; 2008 Sep; 16(9):1546-55. PubMed ID: 18648350
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
[TBL] [Abstract][Full Text] [Related]
17. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.
Ikeda K; Wakimoto H; Ichikawa T; Jhung S; Hochberg FH; Louis DN; Chiocca EA
J Virol; 2000 May; 74(10):4765-75. PubMed ID: 10775615
[TBL] [Abstract][Full Text] [Related]
18. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
Kambara H; Okano H; Chiocca EA; Saeki Y
Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
[TBL] [Abstract][Full Text] [Related]
19. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24.
Oosterhoff D; Pinedo HM; Witlox MA; Carette JE; Gerritsen WR; van Beusechem VW
Gene Ther; 2005 Jun; 12(12):1011-8. PubMed ID: 15729367
[TBL] [Abstract][Full Text] [Related]
20. Active immunotherapy: oncolytic virus therapy using HSV-1.
Todo T
Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
